Invent Medic signs framework agreement for Efemia bladder support with Swedish healthcare region after completed public procurement

Invent Medic announces that the company has signed a framework agreement as provider of the product Efemia bladder support to Region Värmland in Sweden after a completed public procurement process. The agreement comes into effect on May 1, 2020, and it is valid for two years with an option for the region to extend the agreement with up to two years.

This is Invent Medic’s first delivery agreement based on a public procurement, and it is thus an important step towards the company’s goal to sign agreements for Efemia with all public healthcare regions in Sweden. It also provides a good indication on the product’s competitiveness in preparation for expected equivalent public procurement processes in larger European countries such as the UK and Germany.

“This agreement clearly shows that Efemia can be accepted in public procurements in the stress urinary incontinence (SUI) segment in Sweden. This bodes well for upcoming public procurements and our continued ambitious expansion in Europe and the US in the coming years,” says Invent Medic’s CEO Karin Bryder.

Up until today, Efemia is available in Sweden, Norway, Denmark, the UK, Germany, the Netherlands and Belgium. Invent Medic is also working hard to launch the product in additional European markets and in the US in the coming years. There is a major interest in Efemia from public and private healthcare entities, and there is a substantial need for innovation in the segment as some pelvic mesh implants used in the most common type of SUI surgery are banned in markets including the US, the UK and Australia.

For more information please contact
Karin Bryder, CEO
Phone: +46 (0)723811710
E-mail: info@inventmedic.com

About Invent Medic
Invent Medic Sweden AB (Invent Medic) is a Swedish company developing innovative products with the aim to improve women’s health and quality of life. The company’s products are to be safe, effective and easy to use. The finished women’s health products are sold through the company’s Arcamea brand. Invent Medic’s first product, Efemia, is a CE-certified and patented medical technology product used to reduce stress urinary incontinence (SUI) that was shown to reduce urine leakage with 77 percent during usage in a clinical study. The product is based on the same scientific principle as the TVT method, the premier surgical treatment for SUI. Invent Medic’s share is listed on the Spotlight Stock Market with the ticker symbol IMS, and the share’s ISIN code is SE0007603402. More information can be found at www.inventmedic.com and www.spotlightstockmarket.com.